Holen Sie sich die Stockscreener-App
5.05
1.81%
0.09
Handel nachbörslich:
4.72
-0.33
-6.53%
Alpha Tau Medical Ltd Aktie (DRTS) Neueste Nachrichten
Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly? - simplywall.st
Alpha Tau Medical (NASDAQ:DRTS) Price Target Lowered to $7.00 at Citigroup - Defense World
What's Next For Alpha Tau: Major Milestones Expected Through Early 2026 - RTTNews
Taking on analysts’ expectations and winning: Alpha Tau Medical Ltd (DRTS) - setenews.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock By Investing.com - Investing.com Canada
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock - Investing.com
Promising Clinical Developments and Innovative Technology Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau price target lowered to $7 from $8 at Citi - TipRanks
Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough - Nasdaq
Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading? - Benzinga
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma - Imaging Technology News
Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University - marketscreener.com
Alpha Tau announces first patient treated in study using Alpha DaRT tech - TipRanks
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks
Alpha Tau (Nasdaq: DRTS) gives first Alpha DaRT brain treatment in OSU GBM study - Stock Titan
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - Sahm
Alpha Tau treats first US patient with Alpha DaRT for glioblastoma - MSN
Alpha Tau Medical (NASDAQ:DRTSW) Trading 6.9% Higher – Here’s What Happened - Defense World
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform international peersMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Is Alpha Tau Medical Ltd. Equity Warrant stock a smart buy before Fed meeting2025 Technical Overview & Reliable Breakout Forecasts - Newser
Why Alpha Tau Medical Ltd. Equity Warrant stock is popular among millennialsMarket Risk Analysis & Low Risk Investment Opportunities - Newser
Will Alpha Tau Medical Ltd. stock rally after Fed decisionsJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - TipRanks
Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium - TipRanks
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - The Manila Times
Alpha Tau Announces Presentation of Two Alpha DaRT - GlobeNewswire
How Alpha Tau Medical Ltd. stock benefits from global expansionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Alpha Tau Medical Ltd. Receives FDA Approval to Initiate A Trial for Patients with Locally Recurrent Prostate Cancer - marketscreener.com
Alpha Tau receives FDA approval to initiate a trial for patients with locally recurrent prostate cancer - marketscreener.com
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Trial - TipRanks
Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - The Manila Times
Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer - Stock Titan
Alpha Tau to Participate in December Investor Conferences - The Manila Times
COO Gat Files To Sell 16,000 Of Alpha Tau Medical Ltd [DRTS] - TradingView
Alpha Tau (NASDAQ: DRTS) to present at Piper Sandler, Sidoti investor events in Dec 2025 - Stock Titan
What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Momentum & Safe Capital Growth Stock Tips - moha.gov.vn
HC Wainwright Has Negative Outlook for DRTS FY2025 Earnings - MarketBeat
What is HC Wainwright’s Forecast for DRTS FY2025 Earnings? - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Reports Q3 2025 Progress and Financials - MSN
Alpha Tau reports Q3 EPS (32c), consensus (12c) - MSN
Alpha Tau Eyes Year-End Japanese Clearance For Alpha DaRT Treatment In Recurrent Head & Neck Cancer - Nasdaq
Alpha Tau Medical Reports Q3 2025 Results and Advances in Cancer Therapy - TipRanks
[6-K] Alpha Tau Medical Ltd. Current Report (Foreign Issuer) | DRTS SEC FilingForm 6-K - Stock Titan
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
How sustainable is Alpha Tau Medical Ltd. Equity Warrant stock dividend payoutMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
How Alpha Tau Medical Ltd. Equity Warrant stock performs in high volatility marketsJobs Report & Daily Entry Point Trade Alerts - newser.com
How Alpha Tau Medical Ltd. Equity Warrant stock responds to policy changesMarket Performance Summary & Capital Protection Trading Alerts - newser.com
Is Alpha Tau Medical Ltd. stock a defensive play in 2025Trade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Applying Elliott Wave Theory to Alpha Tau Medical Ltd. Equity WarrantJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Relative strength of Alpha Tau Medical Ltd. in sector analysis2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):